Obesity Facts (Sep 2024)

Circulating miRNAs as Biomarkers of Subclinical Atherosclerosis associated to Severe Obesity before and after Bariatric Surgery

  • Júlia Carmona-Maurici,
  • David Ricart-Jané,
  • Anna Viñas,
  • Maria Dolores López-Tejero,
  • Iratxe Eskubi-Turró,
  • Antonio Miñarro,
  • Juan Antonio Baena-Fustegueras,
  • Julia Peinado-Onsurbe,
  • Eva Pardina

DOI
https://doi.org/10.1159/000541175

Abstract

Read online

Introduction: severe obesity results in high cardiovascular risk, increasing morbidity and mortality. New and improved methods are needed to detect cardiovascular diseases rapidly in severe obesity. microRNAs (miRNAs) has shown promise as diagnostic tools. This study aimed to identify plasma miRNAs useful as biomarkers of cardiovascular risk (CVR) in people with severe obesity. Methods: The study included 66 people with severe obesity classified in groups with atheroma (n = 32) and free of plaques (n = 34). Plasma samples were collected 1 month before bariatric surgery and at 6 and 12 months of follow-up. Participants were screened for the levels of 188 miRNAs, and 24 promising candidates were individually validated by quantitative polymerase chain reaction. Results: After validation, 5 of the 24 miRNAs showed significant differences over time in both groups: miR-375 increased after bariatric surgery, whereas miR-144-5p, miR-20a-3p, miR-145-5p and miR-21-3p exhibited decreased expression after bariatric surgery. The expression of 3 of the 24 miRNAs also differed between patients with and without atheroma: subjects with plaque had lower miR-126 but higher miR-21-3p and miR-133a-3p. Only miR-133a-3p exhibited exceptional discriminatory ability between subjects with and without plaque (area under the curve, 0.90; 95% confidence interval, 0.81–0.99). Conclusion: A specific signature of c-miRNA comprising miR-375, miR-144-5p, miR-20a-3p, miR-145-5p and miR-21-3p may facilitate CVR monitoring after bariatric surgery. Furthermore, miR-21-3p, miR-126-3p and miR-133a-3p show potential as specific biomarkers for subclinical atherosclerosis, with miR-133a-3p potentially able to diagnose subclinical atherosclerosis early in severe obesity.